GT Biopharma proposes 250 million shares and dilution risk rises for GT Biopharma stock

Published on 10/16/2026 at 01:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

GT Biopharma seeks 250 million shares on November 11, 2026. For GT Biopharma stock, 2,061,052 shares were outstanding on September 30, 2026.

Capital structure and meeting dates

On October 13, 2026, GT Biopharma proposed raising authorized common shares to 250,000,000.
GT Biopharma reported 2,061,052 common shares outstanding as of September 30, 2026.
Stockholders are scheduled to vote on the proposals on November 11, 2026.

GTBP, US36254L4077, Illustration mit AI erstellt.

GT Biopharma (ISIN US36254L4077) is asking stockholders to approve an increase in authorized common shares from 25,000,000 to 250,000,000. The proposal appeared in a definitive proxy statement filed on October 13, 2026, according to StockTitan.

Why the share proposal matters

The proposed authorization would expand the companys capacity for future financings, acquisitions and other corporate transactions. It would not itself issue the additional shares, but the filing says later issuance could dilute earnings per share and voting rights.

The proxy also asks stockholders to approve issuance of at least 19.99 percent of outstanding common shares under the Series M securities purchase agreement. As of September 30, 2026, GT Biopharma reported 2,061,052 common shares outstanding, while the proposed authorization would leave 236,304,825 shares authorized but unissued if approved, according to StockTitan.

What does the proposal mean for dilution?

The central issue is future share supply rather than an immediate change in the outstanding count. The board says the expanded authorization could support funding and transactions, while the same filing identifies dilution of earnings per share and voting rights as a potential effect.

Three developments shape the case

On September 15, 2026, GT Biopharma announced FDA clearance for a new investigational new drug application covering GTB-5550 in multiple myeloma. The planned Phase 1a dose escalation includes up to 6 cohorts, followed by an expansion group of 25 patients, according to GT Biopharma. On September 22, 2026, Nasdaq restored compliance after 10 consecutive sessions above USD 1.00 per share, as reported by MarketWatch. On October 13, 2026, the definitive proxy placed the proposed 250,000,000-share authorization before investors.

Two dates now matter

Internet and telephone voting is due by 11:59 p.m. Eastern Time on November 10, 2026. The special meeting is scheduled for November 11, 2026, at 11:00 a.m. Pacific Time, according to StockTitan.

Nasdaq quote and capital position

GT Biopharma was last at USD 7.36 on Nasdaq on October 15, 2026 at 4:00 p.m. EDT, in after-hours trading. The same dated quote showed a market capitalization of USD 9.3 million and a 52-week range of USD 4.91 to USD 28.75.